From 1957 to 1962, thalidomide caused birth defects in >10,000 children. While the drug was pulled from the market, thalidomide is currently prescribed to treat conditions including leprosy. As a result, a new generation of babies with thalidomide defects is being born in the developing world. This represents a serious problem, as the mechanisms by which thalidomide disrupts development remain unresolved. This lack of resolution is due, in part, to the absence of an appropriate mammalian model for thalidomide teratogenesis. We test the hypothesis that opossum (Monodelphis domestica) is well suited to model human thalidomide defects. Results suggest that opossum embryos exposed to thalidomide display a range of phenotypes (e.g., heart, craniofacial, limb defects) and penetrance similar to humans. Furthermore, all opossums with thalidomide defects exhibit vascular disruptions. Results therefore support the hypotheses that opossums make a good mammalian model for thalidomide teratogenesis, and that thalidomide can severely disrupt angiogenesis in mammals.
|Number of pages||7|
|Early online date||24 Jan 2017|
|Publication status||Published - Jun 2017|
- congenital birth defects
FingerprintDive into the research topics of 'A new mammalian model system for thalidomide teratogenesis: Monodelphis domestica'. Together they form a unique fingerprint.
Thalidomide research guides recognition and compensation for survivors born with Thalidomide damage
Neil Vargesson (Coordinator) & Lynda Erskine (Coordinator)